

Fortis performs NOIDA's First HIPEC procedure to save 61-year-Old Female Cancer patient

- *Hyperthermic Intraperitoneal Chemotherapy (HIPEC) technique ensures that chemo applied to only the affected areas*

NOIDA, 31st January 2020: The doctors at **Fortis Hospital, NOIDA** successfully performed Hyperthermic Intraperitoneal Chemotherapy (HIPEC) procedure to save a 61-year-old female patient diagnosed with Primary Peritoneal Carcinoma here recently. This is the first time that this technology has been used in NOIDA. The team was led by **Dr Jalaj Baxi, Senior Consultant, Surgical Oncology; Dr Kabir Rehmani, Senior Consultant, Surgical Oncology** and **Dr. Mudhasir Ahmed, Consultant, Medical Oncology, Fortis Hospital Noida.**

The new HIPEC therapy is a locally delivered intraperitoneal chemotherapy developed to treat peritoneal surface malignancies. It successfully cures up to stage 3 carcinoma of Peritoneum, Stomach, Colon and Ovary. It is an improvement over the traditional chemotherapy which is given through blood stream. It also doesn't have any adverse side effects as the delivery is localized and systemic absorption in the cancer affected area is minimum to none, which doesn't produce any systemic side effects of a normal chemotherapy. However, it is used only as an adjunct to surgery to decrease local recurrences. It is not a replacement for post-operative systemic chemotherapeutic treatment. The patient was considered for HIPEC as she was scheduled for a cytoreductive surgery and the requisite response after the three systemic chemotherapy did not yield much response.

Speaking about the success of HIPEC therapy, **Dr Jalaj Baxi** shared, *"The treatment protocol consists of a combination of surgery & chemotherapy. All grossly visible peritoneal disease is removed completely by extensive cytoreductive surgery. Then, the abdominal organs are bathed in a chemotherapy solution, at high temperature (41 deg. Celsius) which is maintained by the machine circulation. The high temperature helps in better penetration of the chemotherapeutic agent locally and can treat diseases up to a depth of 2mm. Diseases that are treatable by HIPEC and CRS include Pseudomyxoma Peritonei, Primary Peritoneal Carcinoma, Peritoneal Mesothelioma, Ovarian cancers with peritoneal metastases (recurrent or residual), select cases of Colorectal, gastric & endometrial cancers with peritoneal metastases."*

Press Release

For Immediate Publication

These are tumors that either arise from the peritoneum itself or spread predominantly to and along the peritoneal surface. Usually, there is a latent period during which they are confined to the peritoneal cavity and amenable to CRS and HIPEC therapy. Once the disease spreads outside the peritoneal cavity, the efficacy of the treatment decreases. Such tumors present a therapeutic challenge since the naturally existing blood-peritoneal barrier (a physiological barrier that separates the blood stream and the peritoneal cavity) prevents the intravenous chemotherapy from entering the peritoneal cavity in adequate concentrations to be effective in eradicating the disease.

Dr Kabir Rehmani also said, *“As HIPEC is a locally delivered therapy, it does not have systemic side effects. Due to delivery at high temperature, it causes vasodilation and increases the penetration of chemotherapeutic agents and thus can treat the microscopic disease even up to 2mm. It also enables safe delivery of higher drug doses than systemic chemotherapy, translating into better survival rates.”*

About Fortis Healthcare Limited

Fortis Healthcare Limited is a leading integrated healthcare delivery service provider in India. The healthcare verticals of the company primarily comprise hospitals, diagnostics and day care specialty facilities. Currently, the company operates its healthcare delivery services in India, Dubai and Sri Lanka with 36 healthcare facilities (including projects under development), approximately 9,000 potential beds and over 410 diagnostics centres.

For more information, please contact:

Fortis Healthcare Ltd	Avian Media
<p>Mansi Jhamb: +91 9873136120 mansi.jhamb@fortishealthcare.com</p> <p>Head Corporate Communications: Ajey Maharaj: +91 9871798573 ajey.maharaj@fortishealthcare.com</p>	<p>Vatika Batra: + 91 9711981753 vatika@avianwe.com</p>